The synergistic effects of these multiple mechanisms not only enhance patients’ quality of life but also provide new therapeutic strategies for the comprehensive management of non-diabetic CKD, highlighting the important role and broad application prospects of SGLT-2 inhibitors in modern nephrology (16). Here, SLC5A2 is linked to chronic kidney disease.